var data={"title":"Ibandronate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ibandronate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6349?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ibandronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ibandronate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181336\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Boniva</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181350\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Bisphosphonate Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181338\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postmenopausal osteoporosis (treatment):</b> <b>Note:</b> Consider discontinuing after 3 to 5 years of use for osteoporosis in patients at low-risk for fracture. Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 150 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 3 mg every 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postmenopausal osteoporosis (prevention):</b> Oral: 150 mg once monthly. <b>Note: </b>Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia of malignancy (off-label use):</b> IV: 2 to 6 mg over 1-2 hours (Pecherstorfer 2003; Ralston 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Metastatic bone disease due to breast cancer (off-label use):</b> IV: 6 mg every 3 to 4 weeks (Diel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Missed doses:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: If once-monthly oral dose is missed, it should be given the next morning after remembered if the next month&rsquo;s scheduled dose is &gt;7 days away. If the next month&rsquo;s scheduled dose is within 7 days, wait until the next month&rsquo;s scheduled dose. May then return to the original monthly schedule (original scheduled day of the month). Do not give &gt;150 mg within 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: If an IV dose is missed, it should be administered as soon as it can be rescheduled. Thereafter, it should be given every 3 months from the date of the last injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181339\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181340\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oncologic uses (off-label): IV: CrCl &lt;30 mL/minute: 2 mg every 3 to 4 weeks (von Moos 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181341\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, ibandronate does not undergo hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181317\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Boniva: 3 mg/3 mL (3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg/3 mL (3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg/3 mL (3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Boniva: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181305\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11441255\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Boniva injection: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021858s022lbl.pdf#page=18&amp;token=ra7janPAv1YRrOFAM9BKIIpVLIej0Z1yDSS/bJV/MED4NQFxjYstit4gdCjFPT3E1ZDsUyoVqHRINNlUA93bvjilTLXjJUSIVG96xz0s4cnXUfsl6EQEZ375JNOXd9G1&amp;TOPIC_ID=8887\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021858s022lbl.pdf#page=18</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Boniva tablets: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021455s021lbl.pdf#page=19&amp;token=86rBLf3OKRSpaeoka+6JAlhyBo0nJ8JrH5Q4cl6JSHt0uoJ1vRpBkFtNgZnHvEYS8r7lQ52VknKapadvbeXIjT6lT+RPxEK6fCy77SoJbBgYuouIAkb81EDVHD+COXg9&amp;TOPIC_ID=8887\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021455s021lbl.pdf#page=19</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181319\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer 60 minutes before the first food or drink of the day (other than water) and prior to taking any oral medications or supplements (eg, calcium, antacids, vitamins). Ibandronate should be taken in an upright position with a full glass (6-8 oz) of plain water and the patient should avoid lying down for 60 minutes to minimize the possibility of GI side effects. Mineral water with a high calcium content should be avoided. The tablet should be swallowed whole; do not chew or suck. Do not eat or drink anything (except water) for 60 minutes following administration of ibandronate. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as a 15-30 second bolus intravenously; avoid paravenous or intraarterial administration (may cause tissue damage). Do not mix with calcium-containing solutions or other drugs. For osteoporosis, do not administer more frequently than every 3 months. Infuse over 1 hour for metastatic bone disease due to breast cancer (Diel, 2004) and over 1-2 hours for hypercalcemia of malignancy (Pecherstorfer, 2003; Ralston, 1997). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181318\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postmenopausal osteoporosis: </b>Treatment and prevention of osteoporosis in postmenopausal females.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: The optimal duration has not been determined. Safety and efficacy for osteoporosis treatment are based on clinical data of 3-years duration (oral) and 1-year duration (IV). All patients on bisphosphonate therapy should be re-evaluated periodically for the need to continue therapy. Consider discontinuing after 3 to 5 years in patients at low-risk for fracture. Re-evaluate fracture risk periodically in patients who discontinue therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474814\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hypercalcemia of malignancy; Metastatic bone disease due to breast cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181309\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentages vary based on frequency of administration (daily vs monthly). Unless specified, percentages are reported with oral use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (2% to 34%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 7%), dizziness (1% to 4%), fatigue (3%), insomnia (1% to 2%), depression (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (5% to 8%), diarrhea (2% to 7%), nausea (4% to 5%), dental disease (4%), constipation (3% to 4%), vomiting (3%), gastritis (2%), gastroenteritis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (2% to 6%), cystitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Acute phase reaction-like symptoms (IV: 10%; oral: 3% to 9%), hypersensitivity reaction (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (4% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (1% to 8%), arthralgia (4% to 9%), myalgia (1% to 6%), arthropathy (4%), weakness (4%), localized osteoarthritis (1% to 3%), muscle cramps (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (3% to 10%), pneumonia (6%), nasopharyngitis (3% to 4%), flu-like symptoms (1% to 3%), pharyngitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Acute renal failure, anaphylactic shock, anaphylaxis, angioedema, bronchospasm, bullous dermatitis, erythema multiforme, exacerbation of asthma, femur fracture (diaphyseal or subtrochanteric), hypocalcemia, iritis, musculoskeletal pain (bone, joint, or muscle; incapacitating), ophthalmic inflammation, osteonecrosis (oro-facial sites including the external auditory canal), osteonecrosis of the jaw, prolonged Q-T interval on ECG (Bonilla 2014), scleritis, Stevens-Johnson syndrome, uveitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181322\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to ibandronate or any component of the formulation; hypocalcemia; oral tablets are also contraindicated in patients unable to stand or sit upright for at least 60 minutes and in patients with abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for bisphosphonates is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181307\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority of cases have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3-5 years) therapy may be at an increased risk. Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Discontinue intravenous ibandronate therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue if new or worsening symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Allergic reactions, including anaphylactic reaction/shock (some fatal), angioedema, bronchospasm, exacerbation of asthma, rash, Stevens-Johnson syndrome, erythema multiforme, and dermatitis bullous have been reported; discontinue immediately if anaphylactic or other severe hypersensitivity/allergic reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Hypocalcemia has been reported with the use of bisphosphonates. Prior to therapy initiation, hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with monthly IV antiresorptive therapy compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer&rsquo;s labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ and clinical judgment by physician and/or oral surgeon should be used. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary in patients receiving oral bisphosphonates for &lt;4 years who have no clinical risk factors (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for &gt;4 years <b>or</b> in patients receiving oral bisphosphonates for &lt;4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month drug free period prior to invasive dental procedures based on a theoretical benefit. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of oral bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use not recommended with severe renal impairment (CrCl &lt;30 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Intravenous bisphosphonates may cause transient decreases in serum calcium and have also been associated with renal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: In the management of osteoporosis, re-evaluate the need for continued therapy periodically; the optimal duration of treatment has not yet been determined. Consider discontinuing after 3-5 years of use in patients at low-risk for fracture; following discontinuation, re-evaluate fracture risk periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299500\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181311\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8887&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Magaldrate; Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181332\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may reduce absorption; mean oral bioavailability is decreased up to 90% when given with food. Management: Take with a full glass (6-8 oz) of plain water, at least 60 minutes prior to any food, beverages, or medications. Mineral water with a high calcium content should be avoided. Wait at least 60 minutes after taking ibandronate before taking anything else.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181324\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic, 2008; Stathopoulos, 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic, 2008; Levy, 2009; Stathopoulos, 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla, 2010; Pereira, 2012;  Stathopoulos, 2011). Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic, 2008; Stathopoulos, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20471831\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ibandronate is excreted into breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181325\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Calcium: 1,000 mg/day (men: 50 to 70 years) <b>or</b> 1,200 mg/day (women &ge;51 years and men &ge;71 years) (IOM 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vitamin D: 800 to 1,000 int. units daily (men and women &ge;50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 int. units daily (men and women &le;70 years) <b>or</b> 800 int. units daily (men and women &ge;71 years) (IOM 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibandronate tablet should be taken with a full glass (6 to 8 oz) of plain water, at least 60 minutes prior to any food, beverages, or medications. Mineral water with a high calcium content should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181315\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Bone mineral density (BMD) should be evaluated 1 to 2 years  after initiating therapy and every 2 years thereafter (NOF [Cosman 2014]); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider measuring biochemical markers of bone turnover</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Serum creatinine prior to each IV dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303145\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9.0 to 11.0 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181306\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181321\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Terminal V<sub>d</sub>: 90 L; 40% to 50% of circulating ibandronate binds to bone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 85.7% to 99.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Minimal; reduced ~90% following standard breakfast</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 150 mg dose: Terminal: 37 to 157 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Terminal: ~5 to 25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (50% to 60% of absorbed dose, excreted as unchanged drug); feces (unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422242\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Boniva Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/3 mL (3 mL): $632.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ibandronate Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/3 mL (3 mL): $505.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Boniva Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (3): $687.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ibandronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (3): $416.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854895\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abrion (ES);</li>\n      <li>Ai Ben (CN);</li>\n      <li>Anabon (KR);</li>\n      <li>Bandrobon (AR);</li>\n      <li>Bonat (IL);</li>\n      <li>Bondex (KR);</li>\n      <li>Bondria (LK);</li>\n      <li>Bondronat (AE, AT, AU, BE, BH, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FR, GR, HK, HR, HU, ID, IE, IS, IT, KW, LB, LU, LV, MT, MX, NL, NZ, PE, PL, QA, RO, RU, SA, SE, SI, SK, TH, TW);</li>\n      <li>Bondronat IV (PH);</li>\n      <li>Boni-M (KR);</li>\n      <li>Bonviva (AE, AT, BE, BG, BH, BR, CH, CL, CO, CU, CY, CZ, DE, DK, EC, EE, ES, ET, FI, FR, GB, GR, HK, HR, HU, ID, IE, IS, IT, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VN, ZW);</li>\n      <li>Drofen (VN);</li>\n      <li>Etanorden (BG);</li>\n      <li>Ibabon (KR);</li>\n      <li>Ibandro (LK);</li>\n      <li>Ibrac (EC);</li>\n      <li>Idena (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Ipexal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oseban (EC);</li>\n      <li>Ostex (TH);</li>\n      <li>Ribonne (KR);</li>\n      <li>Tefal (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Author Unknown, &quot;Safety Update: Bone-Building Drugs: Risks Explained,&quot; <i>Consum Rep Health</i>, 2006, 18(5):3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrett J, Worth E, Bauss F, et al, &ldquo;Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update,&rdquo; <i>J Clin Pharmacol</i>, 2004, 44(9):951-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15317823/pubmed\" target=\"_blank\" id=\"15317823\">15317823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK. Management of osteoporosis in a pre-menopausal woman. <i>Best Pract Res Clin Rheumatol</i>. 2010;24(3):313-327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonilla IM, Vargas-Pinto P, Nishijima Y, et al. Ibandronate and ventricular arrhythmia risk [published online December 20, 2013]. <i>J Cardiovasc Electrophysiol</i>. 2014;25(3):299-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/24256556/pubmed\" target=\"_blank\" id=\"24256556\">24256556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boniva injection (ibandronate) [prescribing information]. South San Francisco, CA: Genetech USA, Inc; December 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/24256556/pubmed\" target=\"_blank\" id=\"24256556\">24256556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boniva tablets (ibandronate) [prescribing information]. South San Francisco, CA: Genetech USA, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25182228/pubmed\" target=\"_blank\" id=\"25182228\">25182228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15251160\"></a>Diel IJ, Body JJ, Lichinitser MR, et al, &ldquo;Improved Quality of Life After Long-Term Treatment With the Bisphosphonate Ibandronate in Patients With Metastatic Bone Disease Due to Breast Cancer,&rdquo; <i>Eur J Cancer</i>, 2004, 40(11):1704-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15251160/pubmed\" target=\"_blank\" id=\"15251160\">15251160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30(12):1146-1148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durie BG, Katz M, and Crowley J, &quot;Osteonecrosis of the Jaw and Bisphosphonates,&quot; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16000365/pubmed\" target=\"_blank\" id=\"16000365\">16000365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards BJ, Hellstein JW, Jacobsen PL, et al, &quot;Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,&quot; <i> J Am Dent Assoc</i>, 2008, 139(12):1674-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19047674/pubmed\" target=\"_blank\" id=\"19047674\">19047674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filleul O, Crompot E, and Saussez S, &quot;Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,&quot; <i>J Cancer Res Clin Oncol</i>, 2010, 136(8):1117-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20508948/pubmed\" target=\"_blank\" id=\"20508948\">20508948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs,&quot; <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22041409/pubmed\" target=\"_blank\" id=\"22041409\">22041409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs,&quot; 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf.  Accessed February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25414052/pubmed\" target=\"_blank\" id=\"25414052\">25414052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. <i>Bone</i>. 2009;44(3):428-430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo; <i>J Oral Maxillofac Surg</i>, 2010, 68(2):243-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19772941/pubmed\" target=\"_blank\" id=\"19772941\">19772941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo; <i>Menopause</i>, 2010, 17(1):25-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20061894/pubmed\" target=\"_blank\" id=\"20061894\">20061894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo; <i>J Oral Maxillofac Surg</i>, 2005, 63(11):1567-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16243172/pubmed\" target=\"_blank\" id=\"16243172\">16243172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo; <i>J Oral Maxillofac Surg</i>, 2007, 65(3):415-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/17307586/pubmed\" target=\"_blank\" id=\"17307586\">17307586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12783289\"></a>Pecherstorfer M, Steinhauer EU, Rizzoli R, et al, &quot; Efficacy and Safety of Ibandronate in the Treatment of Hypercalcemia of Malignancy: A Randomized Multicentric Comparison to Pamidronate,&quot; <i>Support Care Cancer</i>, 2003, 11(8):539-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/12783289/pubmed\" target=\"_blank\" id=\"12783289\">12783289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Rev Bras Reumatol</i>. 2012;52(4):580-593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9010041\"></a>Ralston SH, Thi&eacute;baud D, Herrmann Z, et al, &quot;Dose-Response Study of Ibandronate in the Treatment of Cancer-Associated Hypercalcaemia,&quot; <i>Br J Cancer</i>, 1997, 75(2):295-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/9010041/pubmed\" target=\"_blank\" id=\"9010041\">9010041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero S, Gralow J, Marx RE, et al, &quot;Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2006, 2(1):7-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo; <i>JAMA</i>, 2010, 304(13):1480-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20924014/pubmed\" target=\"_blank\" id=\"20924014\">20924014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo; <i>J Bone Miner Res</i>, 2010, 25(11):2267-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/20842676/pubmed\" target=\"_blank\" id=\"20842676\">20842676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. <i>Hormones (Athens)</i>. 2011;10(4):280-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart AF, &quot;Clinical Practice. Hypercalcemia Associated With Cancer,&quot; <i>N Engl J Med</i>, 2005, 352(4):373-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15673803/pubmed\" target=\"_blank\" id=\"15673803\">15673803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tripathy D, Body JJ, and Bergstrom B, &ldquo;Review of Ibandronate in the Treatment of Metastatic Bone Disease: Experience From Phase III Trials,&rdquo; <i>Clin Ther</i>, 2004, 26(12):1947-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/15823760/pubmed\" target=\"_blank\" id=\"15823760\">15823760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Poznak CH, Temin S, Yee GC, et al, &ldquo;American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2011, 29(9):1221-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/21343561/pubmed\" target=\"_blank\" id=\"21343561\">21343561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Moos R, &ldquo;Bisphosphonate Treatment Recommendations for Oncologists,&rdquo; <i>Oncologist</i>, 2005, 10 (Suppl 1):19-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/16264109/pubmed\" target=\"_blank\" id=\"16264109\">16264109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo; <i>N Engl J Med</i>, 2009, 360(1):89-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibandronate-drug-information/abstract-text/19118315/pubmed\" target=\"_blank\" id=\"19118315\">19118315</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8887 Version 184.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181336\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181350\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181338\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F181339\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F181340\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F181341\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181317\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181305\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11441255\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181319\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181318\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474814\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181309\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181322\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181307\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299500\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181311\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F181332\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181324\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20471831\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F181325\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181315\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21303145\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181306\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181321\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422242\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F854895\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8887|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ibandronate-patient-drug-information\" class=\"drug drug_patient\">Ibandronate: Patient drug information</a></li></ul></div></div>","javascript":null}